Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury - PubMed (original) (raw)
Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury
Asim Mahmood et al. J Neurotrauma. 2004 Jan.
Abstract
This study was designed to investigate the effects of intravenous administration of marrow stromal cells (MSCs) on the expression of growth factors in rat brain after traumatic brain injury (TBI). The fate of transplanted MSCs and expression of growth factors was examined by immunohistochemistry. In addition, the level of growth factors was measured quantitatively using enzyme linked immunosorbent assay (ELISA). Growth factors that were studied included nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and basic fibroblast growth factor (bFGF). For immunohistochemical studies, 12 male Wistar rats were subjected to TBI and then divided into three groups with the first group receiving no treatment, the second group receiving saline (placebo) and the third group receiving MSCs intravenously 1 day after TBI. The neurological function of rats was studied by using Rotarod motor test and modified neurological severity scores. The animals were sacrificed 15 days after TBI and brain sections stained by immunohistochemistry to study the distribution of MSCs as well as expression of growth factors NGF, BDNF, and bFGF. For quantitative analysis, a second set of male Wistar rats (n = 18) was subjected to TBI and then injected with either saline (n = 9) or MSCs (n = 9) 1 day after injury. These rats were sacrificed on days 2, 5, and 8 after TBI and brain extracts used to measure NGF, BDNF, and bFGF. We found that after transplantation, MSCs preferentially migrated into the injured hemisphere and there was a statistically significant improvement in the functional outcome of MSC-treated rats compared to control rats. NGF, BDNF, and bFGF were expressed in the injured brain of both treated as well as control rats; however, quantitative ELISA studies showed that expression of NGF and BDNF was significantly increased (p < 0.05) in the treated group. This study shows that intravenous administration of MSCs after TBI increases the expression of growth factors (NGF, BDNF), which possibly contributes to the improvement in functional outcome seen in these rats.
Similar articles
- Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury.
Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M. Lu D, et al. J Neurotrauma. 2001 Aug;18(8):813-9. doi: 10.1089/089771501316919175. J Neurotrauma. 2001. PMID: 11526987 - Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: growth factor production.
Chen X, Katakowski M, Li Y, Lu D, Wang L, Zhang L, Chen J, Xu Y, Gautam S, Mahmood A, Chopp M. Chen X, et al. J Neurosci Res. 2002 Sep 1;69(5):687-91. doi: 10.1002/jnr.10334. J Neurosci Res. 2002. PMID: 12210835 - Systematic review and meta-analysis of efficacy of mesenchymal stem cells on locomotor recovery in animal models of traumatic brain injury.
Peng W, Sun J, Sheng C, Wang Z, Wang Y, Zhang C, Fan R. Peng W, et al. Stem Cell Res Ther. 2015 Mar 26;6(1):47. doi: 10.1186/s13287-015-0034-0. Stem Cell Res Ther. 2015. PMID: 25881229 Free PMC article. Review. - Endogenous neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy.
Mattson MP, Scheff SW. Mattson MP, et al. J Neurotrauma. 1994 Feb;11(1):3-33. doi: 10.1089/neu.1994.11.3. J Neurotrauma. 1994. PMID: 8201625 Review.
Cited by
- Mesenchymal stem cells reduce long-term cognitive deficits and attenuate myelin disintegration and microglia activation following repetitive traumatic brain injury.
Wang LW, Chio CC, Chao CM, Chao PY, Lin MT, Chang CP, Lin HJ. Wang LW, et al. Sci Prog. 2024 Jan-Mar;107(1):368504241231154. doi: 10.1177/00368504241231154. Sci Prog. 2024. PMID: 38425276 Free PMC article. - Non-pharmacological interventions for traumatic brain injury.
Davis CK, Arruri V, Joshi P, Vemuganti R. Davis CK, et al. J Cereb Blood Flow Metab. 2024 May;44(5):641-659. doi: 10.1177/0271678X241234770. Epub 2024 Feb 22. J Cereb Blood Flow Metab. 2024. PMID: 38388365 Review. - Stem Cell Therapy in Children with Traumatic Brain Injury.
Lin WY, Wu KH, Chen CY, Guo BC, Chang YJ, Lee TA, Lin MJ, Wu HP. Lin WY, et al. Int J Mol Sci. 2023 Sep 28;24(19):14706. doi: 10.3390/ijms241914706. Int J Mol Sci. 2023. PMID: 37834152 Free PMC article. Review. - Silk fibroin carriers with sustained release capacity for treating neurological diseases.
Huang X, An Y, Yuan S, Chen C, Shan H, Zhang M. Huang X, et al. Front Pharmacol. 2023 May 5;14:1117542. doi: 10.3389/fphar.2023.1117542. eCollection 2023. Front Pharmacol. 2023. PMID: 37214477 Free PMC article. Review. - Controlled release of canine MSC-derived extracellular vesicles by cationized gelatin hydrogels.
Yoshizaki K, Nishida H, Tabata Y, Jo JI, Nakase I, Akiyoshi H. Yoshizaki K, et al. Regen Ther. 2022 Dec 10;22:1-6. doi: 10.1016/j.reth.2022.11.009. eCollection 2023 Mar. Regen Ther. 2022. PMID: 36582604 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical